PRTN3 and systemic lupus erythematosus: Anti-PR3 antibodies tested positive in only 7 (4.86%) of all SLE patients, whereas anti-MPO antibodies were positive in 14 (9.27% of all SLE patients) without statistically significant differences between SLE groups (p > 0.05 for both).